97322-87-7 GXPHKUHSUJUWKP-UHFFFAOYNA-N GXPHKUHSUJUWKP-UHFFFAOYSA-N Troglitazone DTXSID8023719 79-94-7 VEORPZCZECFIRK-UHFFFAOYSA-N VEORPZCZECFIRK-UHFFFAOYSA-N 3,3',5,5'-Tetrabromobisphenol A 3,3’,5,5’-Tetrabromobisphenol A (Tetrabromobisphenol A) (Phenol, 4,4'-(1-methylethylidene)bis[2,6-dibromo-) (TBBPA) Phenol, 4,4'-(1-methylethylidene)bis[2,6-dibromo- 2, 2-Bis (4'-hydroxy-3',-5'-dibromophenyl) propane 2,2',6,6'-Tetrabrom-4,4'-isopropylidendiphenol 2,2',6,6'-tetrabromo-4,4'-isopropilidendifenol 2,2',6,6'-tetrabromo-4,4'-isopropylidenediphenol 2,2',6,6'-Tetrabromobisphenol A 2,2-Bis(3,5-dibromo-4-hydroxyphenyl)propane 2,2-Bis(4-hydroxy-3,5-dibromophenyl)propane 3,5,3',5'-Tetrabromobisphenol A 4,4'-(1-Methylethylidene)bis[2,6-dibromophenol] 4,4'-Isopropylidenebis[2,6-dibromophenol] BIS(PHENOL, 2,6-DIBROMO), 4,4'-(1-METHYLETHYLIDENE) BISPHENOL A, TETRABROMO- BISPHENOL, 4,4'-(1-METHYLETHYLIDENE)TETRABROMO- Bromdian Fire Guard 2000 Firemaster BP 4A NSC 59775 Phenol, 4,4'-isopropylidenebis[2,6-dibromo- Saytex CP 2000 Saytex RB 100 Saytex RB 100PC Tetrabromobisphenol A TETRABROMOBISPHENOL-A Tetrabromodian Tetrabromodiphenylolpropane DTXSID1026081 PR:000013058 PR peroxisome proliferator-activated receptor gamma PR:000036194 PR eukaryotic protein CL:0008019 CL mesenchymal cell PR:Q3U4N7 PR IGF-like family receptor 1 (mouse) D005354 MESH Fibrosarcoma D008080 MESH liposarcoma D006394 MESH hemangiosarcoma GO:0035357 GO peroxisome proliferator activated receptor signaling pathway GO:0045444 GO fat cell differentiation GO:0046903 GO secretion GO:0010463 GO mesenchymal cell proliferation GO:0010467 GO gene expression 2 WIKI decreased 1 WIKI increased Troglitazone 2016-11-29T18:42:26 2016-11-29T18:42:26 Tetrabromobisphenol A 2017-03-10T00:10:21 2018-07-20T05:36:51 10117 NCBI Rattus rattus 10090 NCBI mouse Activation of specific nuclear receptors, PPAR-gamma activation Molecular CL:0000182 CL hepatocyte AOPWiki 2016-11-29T18:41:28 2017-09-16T10:17:02 Increased, adipogenesis Cellular CL:0000255 CL eukaryotic cell AOPWiki 2016-11-29T18:41:28 2017-09-16T10:17:02 Increased, secretion of local growth factors Cellular CL:0000255 CL eukaryotic cell AOPWiki 2016-11-29T18:41:28 2017-09-16T10:17:02 Increased, proliferation of mesenchymal cells Cellular CL:0008019 CL mesenchymal cell AOPWiki 2016-11-29T18:41:28 2017-09-16T10:17:03 Increased, IGF-1 (mouse) Cellular CL:0000255 CL eukaryotic cell AOPWiki 2016-11-29T18:41:28 2017-09-16T10:17:03 Increased, Firbrosarcoma Tissue UBERON:0011824 UBERON fibrous connective tissue AOPWiki 2016-11-29T18:41:28 2017-09-16T10:17:03 Increased, liposarcoma Tissue UBERON:0001013 UBERON adipose tissue AOPWiki 2016-11-29T18:41:28 2017-09-16T10:17:03 Increased, hemagiosarcoma Tissue UBERON:0004638 UBERON blood vessel endothelium AOPWiki 2016-11-29T18:41:28 2017-09-16T10:17:04 #<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b42eac73190> AOPWiki 2016-11-29T18:41:36 2016-12-03T16:38:03 #<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b42eacc3190> AOPWiki 2016-11-29T18:41:36 2016-12-03T16:38:03 #<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b42ead436d8> AOPWiki 2016-11-29T18:41:36 2016-12-03T16:38:03 #<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b42ead701b0> AOPWiki 2016-11-29T18:41:36 2016-12-03T16:38:03 #<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b42eaddfe98> AOPWiki 2016-11-29T18:41:36 2016-12-03T16:38:03 #<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b42eadf02c0> AOPWiki 2016-11-29T18:41:36 2016-12-03T16:38:03 #<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b42eae09270> AOPWiki 2016-11-29T18:41:36 2016-12-03T16:38:03 #<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b42eaf34528> AOPWiki 2016-11-29T18:41:36 2016-12-03T16:38:03 PPARgamma-related sarcomas Agnes Aggy <p>Cancer AOP Workgroup. National Health and Environmental Effects Research Laboratory, Office of Research and Development, Integrated Systems Toxicology Division, US Environmental Protection Agency, Research Triangle Park, NC. Corresponding author for wiki entry (wood.charles@epa.gov)</p> BY-SA 1.29 1.0 <p>This putative adverse outcome pathway (AOP) outlines potential key events leading to a tumor outcome in standard carcinogenicity models. This information is based largely on modes of action described previously in cited literature sources and is intended as a resource template for AOP development and data organization. Presentation in this Wiki does not indicate EPA acceptance of a particular pathway for a given reference agent, only that the information has been proposed in some manner. In addition, this putative AOP relates to the model species indicated and does not directly address issues of human relevance.</p> <p>&nbsp;</p> adjacent Not Specified High adjacent Not Specified High adjacent Not Specified High adjacent Not Specified High adjacent Not Specified High adjacent Not Specified High non-adjacent Not Specified High non-adjacent Not Specified Moderate High Moderate Not Specified <p>1. Cohen, S. M. (2005). Effects of PPARgamma and combined agonists on the urinary tract of rats and other species. Toxicological sciences&nbsp;: an official journal of the Society of Toxicology 87(2), 322-7, 10.1093/toxsci/kfi266.</p> <p>2. Hardisty, J. F., Elwell, M. R., Ernst, H., Greaves, P., Kolenda-Roberts, H., Malarkey, D. E., Mann, P. C., and Tellier, P. A. (2007). Histopathology of hemangiosarcomas in mice and hamsters and liposarcomas/fibrosarcomas in rats associated with PPAR agonists. Toxicologic pathology 35(7), 928-41, 10.1080/01926230701748156.</p> <p>3. Kakiuchi-Kiyota, S., Arnold, L. L., Yokohira, M., Koza-Taylor, P., Suzuki, S., Varney, M., Pennington, K. L., and Cohen, S. M. (2011a). Evaluation of direct and indirect effects of the PPARgamma agonist troglitazone on mouse endothelial cell proliferation. Toxicologic pathology 39(7), 1032-45, 10.1177/0192623311422080.</p> <p>4. Kakiuchi-Kiyota, S., Arnold, L. L., Yokohira, M., Suzuki, S., Pennington, K. L., and Cohen, S. M. (2011b). Evaluation of PPARgamma agonists on rodent endothelial cell proliferation. Toxicology 287(1-3), 91-8, 10.1016/j.tox.2011.05.019.</p> <p>5. Long, G. G., Reynolds, V. L., Dochterman, L. W., and Ryan, T. E. (2009). Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR alpha/gamma agonist. Toxicologic pathology 37(6), 741-53, 10.1177/0192623309343775.</p> <p>&nbsp;</p> AOPWiki 2016-11-29T18:41:17 2023-09-25T16:26:52